PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials
PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials
About this item
Full title
Author / Creator
Publisher
US: Oxford University Press
Journal title
Language
English
Formats
Publication information
Publisher
US: Oxford University Press
Subjects
More information
Scope and Contents
Contents
Radiopharmaceuticals have been utilized for men with advanced prostate cancer for decades. Older agents, seldom used today, provided palliation for bone metastatic pain. In 2013, the alpha emitter radium-223 provided a catalyst for the field by prolonging survival in men with metastatic castrate-resistant prostate cancer (mCRPC). Recently radioisot...
Alternative Titles
Full title
PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10166155
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10166155
Other Identifiers
ISSN
1083-7159
E-ISSN
1549-490X
DOI
10.1093/oncolo/oyac279
